LYEL Insider Filing: 8,000 RSUs Vest; 1,453 Shares Sold to Cover Taxes
Rhea-AI Filing Summary
Lyell Immunopharma insider activity by Gary K. Lee: The company's Chief Scientific Officer received 8,000 shares on 08/20/2025 from performance-based restricted stock units, 4,000 of which vested upon certification of performance and 4,000 remain contingent on continued service through 08/20/2026. Following that issuance the reporting person beneficially owned 16,957 shares. On 08/21/2025 the reporting person sold 1,453 shares to satisfy tax withholding from the vested units at a weighted average price of $10.544 per share (sales ranged $10.49–$10.64). After the sale the beneficial ownership reported was 15,504 shares. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
Positive
- 8,000 shares issued to the Chief Scientific Officer as performance-based RSUs, indicating achievement of certified performance criteria
- Clear disclosure of vesting schedule: 4,000 shares issued immediately and 4,000 shares subject to service through 08/20/2026
- Sale was tax-related (sell-to-cover) rather than a larger discretionary disposition, reducing potential governance concerns
Negative
- 1,453 shares sold reducing the reporting person's holdings from 16,957 to 15,504 shares
- Weighted average sale price reported only as a range detail; per-price breakdown is not provided on the form (available upon request)
Insights
TL;DR: Routine insider vesting and tax-related sale; not a directional signal about company fundamentals.
The filing documents a performance-based vesting event delivering 8,000 shares to the Chief Scientific Officer, with half subject to continued service through 08/20/2026, and a contemporaneous sale of 1,453 shares to cover tax withholding at a weighted average price of $10.544. This pattern—vesting plus sell-to-cover—is common and typically reflects compensation mechanics rather than a deliberate market disposal. The post-transaction beneficial ownership is modest (15,504 shares), limiting potential market impact.
TL;DR: Compensation plan functioning as designed; documentation and disclosure appear complete.
The Form 4 explicitly ties the issuance to performance-based restricted stock units granted 02/09/2024 and notes certification by the compensation committee. The split vesting (4,000 shares issued, 4,000 deferred) aligns with typical retention incentives. The sale to cover taxes is disclosed with a weighted average sale price and range; the filer also offers to provide per-price breakdown if requested by SEC staff. Filing was executed via attorney-in-fact with signature dated 08/22/2025, meeting procedural expectations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,453 | $10.544 | $15K |
| Grant/Award | Common Stock | 8,000 | $0.00 | -- |
Footnotes (1)
- Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
